{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"117.2","value":"78.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"379"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 1 (Week 0) post-dose, Geometric mean"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"84.7","value":"10.7"},{"groupId":"OG002","spread":"67.8","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"221"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 2 (Week 4), Geometric mean"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"156.5","value":"1.3"},{"groupId":"OG002","spread":"85.4","value":"4.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"86"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 4 (Week 12), Geometric mean"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"388"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Blood sample were collected at pre-specified timepoints and Tremelimumab concentrations in serum (ug/mL) were reported over time.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set includes all participants who received at least 1 dose of Tremelimumab per the study protocol for whom any PK post-dose data were available (ie, at least 1 non-missing post-dose PK result). T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"To evaluate the PK of Tremelimumab, samples were collected at week 0 (post-dose), week 4, and week 12. Assessed at the final analysis DCO (27Aug2021).","title":"Summary of Tremelimumab Concentration Over Time","type":"SECONDARY","unitOfMeasure":"ug/mL"}